103 related articles for article (PubMed ID: 11288655)
1. What caused this patient's sudden liver dysfunction?
Porterfield LM
RN; 2001 Mar; 64(3):98. PubMed ID: 11288655
[No Abstract] [Full Text] [Related]
2. "Did this drug cause my patient's hepatitis?" and related questions.
Nierenberg DW
Ann Intern Med; 2002 Mar; 136(6):480-3. PubMed ID: 11900502
[No Abstract] [Full Text] [Related]
3. [Meta-analysis shows: insulin sensitizer is safe for the liver].
MMW Fortschr Med; 2002 Oct; 144(40):47. PubMed ID: 12440297
[No Abstract] [Full Text] [Related]
4. Substituting for troglitazone (Rezulin).
Med Lett Drugs Ther; 2000 Apr; 42(1076):36. PubMed ID: 10803176
[No Abstract] [Full Text] [Related]
5. Late-onset troglitazone-induced hepatic dysfunction.
Bell DS; Ovalle F
Diabetes Care; 2000 Jan; 23(1):128-9. PubMed ID: 10857986
[No Abstract] [Full Text] [Related]
6. Troglitazone-associated hepatic failure.
Booth AM; Caldwell SH; Iezzoni JC
Am J Gastroenterol; 2000 Feb; 95(2):557-8. PubMed ID: 10685776
[No Abstract] [Full Text] [Related]
7. A novel antidiabetic drug, troglitazone--reason for hope and concern.
Imura H
N Engl J Med; 1998 Mar; 338(13):908-9. PubMed ID: 9516229
[No Abstract] [Full Text] [Related]
8. Hepatocellular injury in a patient receiving pioglitazone.
Maeda K
Ann Intern Med; 2001 Aug; 135(4):306. PubMed ID: 11511159
[No Abstract] [Full Text] [Related]
9. [A case of drug induced liver injury related pioglitazone].
Hisamochi A; Kumashiro R; Koga Y; Tanaka E; Ide T; Hino T; Murashima S; Ogata K; Kuwahara R; Koga H; Shishido S; Ueno T; Sata M; Eguchi T
Nihon Shokakibyo Gakkai Zasshi; 2003 Mar; 100(3):333-6. PubMed ID: 12696176
[No Abstract] [Full Text] [Related]
10. Summary for patients. Liver damage in a person taking the diabetes drug pioglitazone.
Ann Intern Med; 2002 Mar; 136(6):I65. PubMed ID: 11900516
[No Abstract] [Full Text] [Related]
11. [Pioglitazone].
Kobayashi M; Iwata M; Hiratani K
Nihon Rinsho; 2002 Sep; 60 Suppl 9():429-37. PubMed ID: 12387029
[No Abstract] [Full Text] [Related]
12. Company played down drug's risks, report says.
Gottlieb S
BMJ; 2001 Mar; 322(7288):696. PubMed ID: 11264205
[No Abstract] [Full Text] [Related]
13. Upadate on oral treatments for type II diabetes.
Dykeman J
CANNT J; 2002; 12(1):41-2. PubMed ID: 11979652
[No Abstract] [Full Text] [Related]
14. Diabetes drug Rezulin: take it, but take precautions.
Health News; 1999 May; 5(6):7. PubMed ID: 10546576
[No Abstract] [Full Text] [Related]
15. Thiazolidinediones in diabetes: current status and future outlook.
Camp HS
Curr Opin Investig Drugs; 2003 Apr; 4(4):406-11. PubMed ID: 12808879
[TBL] [Abstract][Full Text] [Related]
16. Thiazolidinedione hepatotoxicity: a class effect?
Tolman KG
Int J Clin Pract Suppl; 2000 Oct; (113):29-34. PubMed ID: 11965828
[TBL] [Abstract][Full Text] [Related]
17. Rezulin to be withdrawn from the market.
Diabetes Technol Ther; 2000; 2(2):289. PubMed ID: 11469272
[No Abstract] [Full Text] [Related]
18. Accelerated hypertension due to rosiglitazone therapy.
Vikram NK; Misra A; Devi JR
Indian Heart J; 2002; 54(6):733. PubMed ID: 12674195
[No Abstract] [Full Text] [Related]
19. Rosiglitazone--useful drug but has side effects.
Vidhya S; Mohan V
J Assoc Physicians India; 2002 Apr; 50():615. PubMed ID: 12164432
[No Abstract] [Full Text] [Related]
20. Lessons from the glitazones: a story of drug development.
Gale EA
Lancet; 2001 Jun; 357(9271):1870-5. PubMed ID: 11410214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]